| Issue Date | Title | Author(s) | Relation | scopus | WOS | Fulltext/Archive link |
|---|---|---|---|---|---|---|
| 2022 | Development of Irinotecan Liposome Armed with Dual-Target Anti-Epidermal Growth Factor Receptor and Anti-Fibroblast Activation Protein-Specific Antibody for Pancreatic Cancer Treatment | Lin, HJ; Liang, TL; Chang, YY; Liu, DZ; Fan, JY; Roffler, SR ; Lin, SY | Pharmaceutics 14(6), 1202 |
